CJC-1295 without DAC 5mg + IPA 5mg

This blend combines a GHRH analogue (CJC-1295 without DAC / Mod GRF 1-29) with a selective ghrelin receptor agonist (Ipamorelin, often abbreviated as IPA). The combination is used in research to explore complementary upstream stimulation of the GH axis through two receptor systems with different signalling characteristics. Mechanistic studies typically examine GH pulsatility, secretion kinetics, and downstream endocrine markers such as IGF-1 pathway activity. Researchers may use combination designs to compare amplitude and timing effects versus single-agent stimulation, while tracking secondary biomarkers to characterise selectivity and broader endocrine signalling footprints.

‍

‍

‍

‍

‍